Art. 17 Regulation (EU) 2016/161

Equivalent unique identifier

In forcesince 2 Oct 2015cited 3×

When placing an equivalent unique identifier for the purposes of complying with Article 47a(1)(b) of Directive 2001/83/EC, the manufacturer shall verify that the structure and composition of the unique identifier placed on the packaging complies, with regard to the product code and the national reimbursement number or other national number identifying the medicinal product, with the requirements of the Member State where the medicinal product is intended to be placed on the market, so that that unique identifier can be verified for authenticity and decommissioned.

  • Opinion of Advocate General Szpunar delivered on 13 January 2022. Novartis Pharma GmbH v Abacus Medicine A/S.Decision

    It may therefore be the case that the parallel trader is required to replace the unique identifier of a medicinal product [In accordance with Article 47a of Directive 2001/83 and Articles 16 and 17 of Delegated Regulation 2016/161.] or to …

    13 Jan 2022 · 62020CC0147

  • Judgment of the Court (Fifth Chamber) of 17 November 2022. Bayer Intellectual Property GmbH v kohlpharma GmbH.Decision

    Article 17 of that delegated regulation, entitled ‘Equivalent unique identifier’, provides: ‘When placing an equivalent unique identifier for the purposes of complying with Article 47a(1)(b) of Directive [2001/83], the manufacturer …

    17 Nov 2022 · 62020CJ0204

  • Judgment of the Court (Fifth Chamber) of 17 November 2022. Novartis Pharma GmbH v Abacus Medicine A/S.Decision

    Article 17 of that delegated regulation, entitled ‘Equivalent unique identifier’, provides: ‘When placing an equivalent unique identifier for the purposes of complying with Article 47a(1)(b) of Directive [2001/83], the manufacturer …

    17 Nov 2022 · 62020CJ0147